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OMOZYGOUS 0 THALASSEMIA, a disease in which there is inadequate production of 0 globin leading to severe anemia, affects thousands of individuals worldwide. Current management of this condition includes the use of regular red blood cell (RBC) transfusions and iron chelation therapy. The development of an effective therapy to increase hemoglobin (Hb) levels in homozygous fJ thalassemia without the use of RBC transfusions could allow normal growth and development, whereas decreasing or eliminating transfusional iron overload, which remains the major cause of death, reduced life expectancy and morbidity in individuals with this disease.' Although bone marrow transplantation can achieve these aims: it is not a therapeutic option for the majority of patients. For some years, there has been interest in increasing yglobin transcription and fetal Hb (HbF) production in patients with , B hemogl~binopathies.~.~ For patients with homozygous fJ thalassemia, increased y-globin production and a reduction in the ratio of a-to non-a-globin could reasonably be expected to ameliorate the seventy of the anemia. To this end, trials of chemotherapeutic agents including 5-azacytielotoxicity, fears of long-term carcinogenesis, and only modest responses to treatment have limited the clinical usefulness of these agents. Erythropoietin has also been used, but responses to this therapy have been variable.L'*L1
There is considerable evidence that butyrate analogues induce erythroid differentiati~n""~ and stimulate HbF production in human erythroid progenitors in v i t r~.~~"~ In vivo, these agents have also been shown to reactivate embryonic globin production in an avian model," delay the switch from fetal to adult globin in ovine fetuses," and to increase HbF production in adult primates.17. [20] [21] [22] In humans, several fatty acids including a amino-butyric acid?' arginine isob~tyramide,~~~" sodium phen y l b~t y r a t e ,~~.~~ propionic acid:' and 2-propylpentanoic (dipropylacetic) acid (unpublished data) have now been shown to stimulate HbF production, suggesting that they may play a role in the treatment of the p-globin disorders. However, previous clinical trials of these agents in &thalassemia have a-globin ratios as measured by levels of mRNA and globin protein in peripheral blood did not correlate with response to treatment. Response to treatment was not associated with the type of p-globin mutation, but baseline erythropoietin levels of greater than 120 mU/mL was seen in all responders and onlytwo of eight nonresponders to SPB. Compliance with treatment was greater than 90% as measured by pill counts. Side effects of the drug included weight gain and/ or edema caused by increase salt load in 2/12, transient epigastric discomfort in 7/12, and abnormal body odor in 3/ 12 subjects. Two splenectomized patients who were not on prophylactic antibiotics developed sepsis while on treatment. We conclude that SPB increases Hb in some patients with thalassemia, but the precise mechanism of action is unknown.
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been limited to relatively short-term trials of the intravenous agent, arginine b~tyrate,".~~.~' and oral i~obutyramide.~.~~ Sodium phenylbutyrate is an orally administered agent originally developed to promote waste nitrogen excretion in the treatment of urea-cycle disorders3' and is currently used for this purpose in an Federal Drug Administration-approved phase I11 trial. Over 100 patient-years experience with this drug has now accumulated with no untoward effects being found. The finding of increased HbF levels in these patients2* stimulated clinical trials of sodium phenylbutyrate in patients with P-hemoglobinopathies.
We report here the first long-term clinical trial of an orally administered fatty acid, sodium phenylbutyrate, in patients with homozygous p thalassemia. This represents the largest clinical trial of any Hb switching agent used in thalassemic patients to date.
PATIENTS AND METHODS
This study was approved by the Joint Committee on Clinical Investigation of the Johns Hopkins Medical Institutions and written informed consent was obtained from all patients. Eleven patients Table 1 . Patients 1 through 7 and 9 through 12 commenced sodium phenylbutyrate therapy during a 21-day inpatient stay in the Johns Hopkins Hospital Clinical Research Unit. Patients 2 and 9 underwent the protocol on two occasions, recommencing sodium phenylbutyrate after S9 and 440 days off treatment. All received 20 g/d of sodium phenylbutyrate (10.6 to 13.8 g/m2/d) given as forty 500-mg tablets in three divided doses: 12 tablets were given with breakfast and 14 tablets with each of lunch and dinner. All were discharged home on medication and were followed from between 31 and 500 days as outpatients. Five of these patients continue on medication.
Patient 8, unable to be transfused because of severe alloimmunization, was receiving intravenous infusions of 5-azacytidine every 3 to 4 weeks' before starting sodium phenylbutyrate therapy. Her therapy was initiated at a lower dose of 12 g/d (9.6 g/m2/d) during a 21-day inpatient stay at the National Institutes of Health, Bethesda, MD. The infusions of S-azacytidine were subsequently discontinued and she continues on sodium phenylbutyrate alone.
All patients were documented to have normal RBC folate levels (and serum folate in the case of regularly transfused patients) before the commencement of therapy and received folic acid 1 mg/d orally while on the protocol.
Blood counts were determined using Coulter STK-S or STK-R counters (Coulter Immunology, Hialeah, FL) with manual spun Hb measurements being performed to overcome any artifactual elevation in automated Hb measurements caused by the presence of nucleated RBCs in the peripheral blood." A Technicon H-l counter was used for the determination of RBC mean corpuscular volume (MCV). Reticulocyte counts were measured with a Sysmex R-1000.34 Percentages of HbF, F cells, and F reticulocytes were measured as previously de~cribed.'~ Globin-chain synthesis was measured by incubating peripheral blood (PB) with tritiated leucine using standard methods36 with globin-chain separation being achieved by high-performance liquid chromatography. PB ratios of a, p-and y-globin mRNA were measured using an RNAase protection assay (RPA I1 kt; Ambion, Inc, Austin, TX). 32P-labeled RNA probes were made complimentary to a 130-bp segment of exon 1 of a globin, a 205-bp segment of exon 2 of p globin and a 170-bp segment of exon 2 of y globin. The protected fragments were separated by electrophoresis on an 8 mol/L urea 6% polyacrylamide gel, located by autoradiography and quantitated by counting the radioactivity of each isolated band in a scintillation counter. Levels of sodium phenylbutyrate, phenylacetate, and phenylacetylglutamine were measured in plasma and urine by previously described method^.^'
Data are expressed as mean ? standard deviation (range) and were compared using the paired Student's r-test. Differences between observed and expected frequencies were compared using a chisquare test.
RESULTS

Changes in Hb.
We divided the patients into two broad categories, responders and nonresponders, based on changes in Hb while on sodium phenylbutyrate therapy (Table 2) . A response was defined as a sustained rise in Hb of greater than 1 g/dL. A sustained increase in Hb of 2.1 t 0.7 g/dL (1.2 to 2.8 g/dL) was seen in 4 of the 8 (50%) patients with homozygous thalassemia not on regular transfusion programs ( Fig I) . Patient 4 showed a progressive increase in Hb over 350 days on therapy, with an acute episode of anemia related to septicemia at day 200 during which she was not transfused. Her Hb peaked at 10.2 g/dL on day 351 and then fell to around 9 g/dL when her dose of sodium phenylbutyrate was reduced by 25% to 15 gld. Interestingly, her sibling, patient 5, also responded to sodium phenylbutyrate therapy with an increase in Hb of 1.8 g/dL over the first 140 days on therapy. Patient 8, who was receiving intravenous infusions of 5-azacytidine at the time sodium phenylbutyrate therapy was commenced, has shown a progressive increase in Hb over more than 450 days, interrupted by an acute episode of anemia related to a major gastrointestinal hemorrhage at day 220. She received two units of blood at this time. Her Hb has continued to increase allowing the 5-azacytidine infusions to be discontinued at day 280. Patient 3 showed an increase in Hb of 1.2 g/dL while on sodium phenylbutyrate, and her Hb had returned to pretreatment levels within 40 days after stopping therapy. Although this increase in Hb is only modest, in the other patients responding to therapy, Hb continued to increase for 500 days or more, suggesting that a trial of only 100 days of sodium phenylbutyrate therapy may have been inadequate to achieve the maximum possible response. Four of the eight nontransfused patients and all three previously regularly transfused patients showed no response to therapy (Table 2, Fig 2) .
F reticulocyte response. All 12 patients showed an increase in the percentage of F reticulocytes after the commencement of sodium phenylbutyrate therapy, with levels at day 21 being 70% It 74% (mean +-1SD; range, 6% to 248%) above baseline levels (P = .001). In all patients, the increased level of F reticulocytes persisted as long as therapy was continued. In five of eight patients who discontinued sodium phenylbutyrate therapy, F reticulocytes decreased rapidly, but in three, nos. 1, 6, and 11, the F reticulocytes remained at the higher level for 4 weeks or more after the cessation of therapy. Two patients, 2 and 9, again showed an increase in F reticulocytes when therapy was recommenced. These changes suggest that the increase in F reticulocytes was directly related to the sodium phenylbutyrate therapy (Fig 3) . Hemoglobin F response. Table 3 outlines the HbF response to sodium phenylbutyrate therapy in each patient, as measured by percentage of HbF, absolute HbF g/&, and cy/ non-a ratios of both globin mRNA and globin-chain synthesis. In those patients responding to therapy, increase in total Hb was not solely explained by increased HbF. In those patients previously on regular transfusion programs, at termination of therapy both HbF% and absolute HbF levels were higher than at baseline, probably reflecting the reduced suppression of erythropoiesis related to fall in Hb and not being necessarily directly attributable to the sodium phenylbutyrate therapy. Ratios of a-to non-a-globin mRNA, measured before therapy and again at day 21 in all patients, showed no uniformity of response to sodium phenylbutyrate therapy, nor was there any correlation between the change in globin mRNA ratios and peripheral Hb levels. Similarly, when repeated in three patients after more than 270 days on therapy, no correlation between ratios of globin mRNA and change in Hb could be shown. In addition to mRNA studies, in three patients, the production of a-and non-cy-globin chains in PB reticulocytes was measured at day 0 and at day 21. Again, in these patients, neither ratios of globin mFWA nor globinchain synthesis seemed related to changes in Hb on therapy.
Patient 12, with sickle p plus thalassemia, did not experience an increase in Hb and, therefore, was called a nonresponder. However, over the first 21 days of therapy, she did show an increase in F reticulocytes (14% to 34%) and F cells (13% to 20%) associated with an increase in HbF% (3.1% to 5.0%). This response to therapy is very similar to those previously seen in patients with homozygous sickle cell di~ease.'~ In sickle thalassemia, an increase in the percentage of HbF is probably a more desirable outcome than increase in Hb. Interestingly, while on therapy, her MCV increased from 67 fL to 74 fL and returned to its pretreatment value when sodium phenylbutyrate therapy was discontinued.
Indicators of hemolysis. The nine patients not on regular transfusion programs showed indirect evidence of a reduction in hemolysis, with significantly lower levels of serum lactate dehydrogenase ( P < .03) and indirect bilirubin ( P = .OOO5) when pretreatment levels were compared with those at day 21 (Table 2) . This was not observed in the transfusiondependent patients, possibly related to the mean fall in Hb of 2.0 g/dL, which occurred in these patients during the 21-day inpatient study period. In contrast, no significant difference was seen in Hb between baseline measurements and day 21 in those patients who were not regularly transfused.
Predictors of increased Hb in response to sodium phenylbutyrate therapy. Response to sodium phenylbutyrate therapy, as defined by a sustained increase in total Hb of greater than 1 g/dL above baseline, did not appear to be predicted by P-globin mutation; baseline percentage of HbF, absolute HbF, or F-reticulocyte levels; or baseline Hb or baseline ato non-a-globin ratios. Similarly, significant falls in lactate dehydrogenase and indirect bilirubin, traditional measures of hemolysis, could be shown in all nontransfused patients with no differences being observed between responders and nonresponders. Interestingly, those patients with baseline erythropoietin levels greater than 120 mU/mL were significantly ( P < .05) more likely to experience an increase in Hb (4/6) than those whose baseline erythropoietin level was below 120 mU/mL (0/6) ( Table 2) . A similar trend existed between baseline HbF percentage in those patients not receiving regular RBC transfusions and response to sodium phenylbutyrate therapy, although this did not reach statistical significance. Of the four patients with baseline HbF less than 40%, none responded to therapy. In contrast, four of the five patients with baseline HbF greater than 40% did respond (P = ,075).
Compliance with sodium phenylbutyrate therapy.
Sodium phenylbutyrate tablets were provided to the patients with a 25-day supply each time; a further supply was provided only when the patient specifically requested more tablets. In this way, compliance was calculated for each patient by comparing the number of tablets dispensed to that prescribed. Compliance with therapy was a problem in only one patient, no. 3, who abruptly discontinued therapy after 100 days, having been 95% compliant up until that time. For the patients as a group, compliance with medication was 97% ? 3%.
PhenyZbuQrate pharmucokinetics. Peak daytime levels of phenylbutyrate, phenylacetate, and phenylacetylglutamine ranged between 0.60 and 1.70 mmol/L, 0.50 and 1 .SO mmol/ L, and 0.56 and 2.67 mmol/L, respectively. Serial-fasting morning plasma levels of phenylacetate, measured in all patients, were less than l .O mmoln and showed no progressive accumulation. Serial 24-hour urine collections performed in 9 of the 12 patients studied showed a mean excretion of 76% 2 13% (53% to 97%) of the molar amount of sodium phenylbutyrate administered as urinary phenylacetylglutamine. Plasma glutamine levels, measured before therapy and again after 2,9, and 21 days on therapy showed no evidence of glutamine depletion. These results are similar to those reported in patients with urea-cycle disorders32." and homozygous sickle cell disease29 treated with sodium phenylbutyrate.
Adverse events occurring on therapy. The daily dose of 20 g of sodium phenylbutyrate contributes 2,460 mg (107 mmol) of sodium to the diet, a significant proportion of the recommended daily intake. While in the hospital, one of the twelve patients (no. 6) developed ankle edema associated with a 3.5% increase in body weight, which resolved spontaneously with dietary modification. After discharge from hospital, one patient (no. 1) required intermittent treatment with a thiazide diuretic and one (no. 8) required an increase in her previous diuretic dose to control peripheral edema. No patient developed hypertension. Epigastric discomfort after use only.
For the ingestion of the tablets was the most common adverse effect, being reported by seven of the twelve patients. Two patients, both splenectomized and not on regular penicillin prophylaxis, had nonfatal episodes of bacterial septicemia: patient 4 developed infection with Streptococcus pneumoniae at day 71 and Plesiomoms shigelloides at day 200, and patient no. 6 developed infection with Staphylococcus epidermidis related to a indwelling central venous catheter at day 24. Patient 8 suffered a hemorrhage from a gastric ulcer at day 220 soon after the commencement of aspirin therapy for long-standing pulmonary hypertension. Patient 1, who had spun Hb levels between 5.1 and 7.5 g / & associated with marked erythroblastosis, developed spinal cord compression requiring irradiation at day 323 and ceased sodium phenylbutyrate therapy. Patient 10 developed a deep venous thrombosis at day 28 with a Hb 5.9 g/dL. Three patients experienced bad body odor while on therapy, which in one, no. 12, caused her to be unable to tolerate the medication long-term, even at half the usual dose. These complaints are probably related to the in vivo @ oxidation of phenylbutyrate to phenylacetate, a compound with an offensive odor secreted as a defense mechanism by the stinkpot turtle.3s
DISCUSSION
This study shows that sodium phenylbutyrate can safely be administered to patients with homozygous @ thalassemia and is well tolerated by the majority. The need to take 40 tablets daily, epigastric discomfort, and the body odor created in some patients are problematic. Poor compliance with this regimen, based on previous experience with this drug, was expected to be a frequent but surprisingly was not, possibly related to the fact that many of these patients had had prior experience with other cumbersome medical interventions including transfusion schedules and iron chelation therapy. However, the oral route of administration has clear advantages over the intravenous route needed for arginine butyrate, particularly because all the evidence available suggests that in the management of the @ hemoglobinopathies, these therapies, if effective, will be needed long-term.
We found that 36% (4/11) of all patients or 50% (418) of nontransfused patients responded to sodium phenylbutyrate when a response was defined as a sustained increase in Hb of more than 1 gjdL over pretreatment values. Clearly, sodium phenylbutyrate can increase Hb in some patients with homozygous @ thalassemia, but is not effective in all of them. Although it seems evident that @-globin mutation alone does not predict response, the fact that two siblings treated in this study both responded to sodium phenylbutyrate therapy raises the possibility that some other genetic factor is involved. Other genetic factors linked and unlinked to the @-globin locus have been shown to effect HbF levels in normal individuals and patients with @ hemoglobin~pathies.~~. ~~ The failure of Hb to increase in patients showing a decrease in levels of lactate dehydrogenase and indirect bilirubin is disappointing and raises interesting questions as to the cause of these changes if not related to decreased hemolysis. Similarly, we have observed increased production in F reticulocytes in all patients treated with this agent to date and the persistence of levels of F reticulocytes higher than baseline in some patients up to a month or more after the cessation of therapy with an agent known to be rapidly metabolized and excreted. Similar observations have been reported after the use of arginine b~tyrate.'~.'~ This uniformity of Freticulocyte response, persistence of response in some patients long after the cessation of therapy, and lack of correlation between changes in F reticulocytes and increased total Hb or increased absolute HbF production may indicate suboptimal increases in HbF insufficient to decrease ineffective erythropoiesis.
The lack of correlation between changes in a-to nonuse only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From a-globin ratios, measured both as mRNA or globin-chain synthesis, and response to therapy raises more questions as to the mechanism of action of these fatty acid compounds. In this study, we were unable to show a correction in a to non-a ratios in patients experiencing increases in Hb and observed a fall in total Hb in one nontransfused patient whose HbF production clearly increased. The recent demonstration of induction of a -as well as y-globin production in butyrate-treated transgenic mice (G. Stamatoyannopoulos, personal communication, December 1993) may help explain some of these observations and suggests that viewing these compounds as selective inducers of y-globin production may have been premature. Similar data exists concerning the use of intravenous arginine butyrate, which was initially reported as a selective stimulator of the human y-globin gene promoter capable of correcting a -to non-a-globin-chain imbalance in patients with thala~semia.'~ Although early reports linking correction of globin-chain imbalance to subsequent increase in Hb with arginine butyrate were encouraging, these changes have not been reproduced in other patients showing a response to therapy.z5 Similarly, the slow nature of the response to therapy reported in the current study, with gradual increases in Hb over 200 to 500 days on therapy is not consistent with a mechanism invoking rapid correction of globin-chain ratios over a few days or weeks.
We observed an inconsistent response to therapy, a decrease in traditional indicators of hemolysis in all nontransfused patients that were not predictive of an increase in Hb, and increases in Hb not entirely explained by increased HbF in those patients who did respond to therapy. This suggests that classic Hb switching, an increase in y-globin production with resultant decrease in globin-chain imbalance, could not explain the increases in Hb seen. Three possible explanations exist: sodium phenylbutyrate (1) caused nonspecific induction of all globin production, ie, a , p, y , and not just y alone; (2) caused nonspecific expansion of RBC mass by the release of thalassemic RBCs previously sequestered in the marrow or by an increase in production of thalassemic RBCs; or (3) caused a prolongation of RBC survival without a change in RBC production. There is evidence to support the first of these (G. Stamatoyannopoulos, personal communication, December 1993) and the latter two lead to testable hypotheses in further patients.
The positive correlation between baseline serum erythropoietin level and the likelihood of responding to therapy is very interesting. This observation, together with the fact that erythropoietin levels in homozygous P thalassemia are generally elevated, but inappropriately so for the degree of anemia, suggests that clinical trials of combination therapy using erythropoietin with sodium phenylbutyrate may be of value. However, it must be remembered that in these patients, erythropoietin levels are related to other factors, such as baseline HbF%41 and as such, erythropoietin may only be a marker of some other factor affecting response.
It is also of interest that an increasing number of structurally related compounds are being shown to increase HbF production in vitro and in vivo in animals, hematologically normal individuals, and patients with P hemoglobinopathies.
Most recently, we have discovered that valproic acid, a drug used for the treatment of epilepsy for the past 20 years, causes increased HbF production in nonanemic individuals4' just as sodium phenylbutyrate was shown to increase HbF production in patients with urea-cycle disorders." Adding to the intrigue is the fact that the compounds reported to date share a relatively small part of their structure in common and appear to be effective at vastly different molar dosages.
Although mechanistically intriguing, and clearly of value to a selected group of patients, butyrate and other fatty acid compounds remain far from being a panacea for all patients with p hemoglobinopathies. The pharmacologic manipulation of HbF remains an inexact and as yet unproven therapy for the P-globin disorders.
